Valeant Pharmaceuticals International, Inc. announced today that it has received approval from the Food and Drug Administration (FDA) for its  Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) Gel microsphere 0.08% for the topical treatment of acne vulgaris.
“We are very pleased that the FDA has approved our new strength of Retin-A Micro as this gives health care providers and patients a new option for the topical treatment of acne vulgaris,” stated J. Michael Pearson, chairman and chief executive officer.  “This new strength will provide physicians and patients another effective treatment and should be a welcome alternative to current strengths. We look forward to launching 0.08% Retin-A Micro in the near future.”